title: [Osteoporosis without fracture: when do we treat?].
abstract: Osteoporosis without prevalent fracture is defined by a low bone mineral density (BMD), which is a risk factor for fracture. We also use the FRAX tool to determine treatment indications. The objective of the treatment is to reduce fracture risk--which has been defined by BMD and clinical risk factors--with various types of therapeutic classes, such as bisphosphonates, strontium ranelate, denosumab and raloxifene. Calcium and vitamin D may be a useful addition.
authors.affiliation: Inserm UMR 1033, université de Lyon, service de rhumatologie et pathologie osseuse, hôpital Edouard-Herriot, 69437 Lyon Cedex 03. roland.chapurlat@inserm.fr
authors.forename: Roland
authors.initials: R
authors.lastname: Chapurlat
mesh_terms: D042241:Early Diagnosis; D050723:Fractures, Bone / Q000175:diagnosis / Q000209:etiology; D006801:Humans; D008954:Models, Biological; D010024:Osteoporosis / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D017410:Practice Guidelines as Topic; D011364:Professional Practice; D012307:Risk Factors